Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Common Equity (2016 - 2025)

Lifecore Biomedical, Inc. \De\ has reported Common Equity over the past 15 years, most recently at $1.3 million for Q2 2025.

  • For Q2 2025, Common Equity fell 88.19% year-over-year to $1.3 million; the TTM value through May 2025 reached $1.3 million, down 88.19%, while the annual FY2025 figure was $1.3 million, 88.19% down from the prior year.
  • Common Equity for Q2 2025 was $1.3 million at Lifecore Biomedical, Inc. \De\, down from $2.2 million in the prior quarter.
  • Over five years, Common Equity peaked at $202.2 million in Q1 2021 and troughed at -$13.6 million in Q3 2023.
  • A 5-year average of $66.4 million and a median of $26.4 million in 2023 define the central range for Common Equity.
  • Biggest five-year swings in Common Equity: tumbled 117.41% in 2023 and later surged 987.19% in 2024.
  • Year by year, Common Equity stood at $155.4 million in 2021, then crashed by 54.23% to $71.1 million in 2022, then crashed by 98.0% to $1.4 million in 2023, then surged by 987.19% to $15.4 million in 2024, then crashed by 91.35% to $1.3 million in 2025.
  • Business Quant data shows Common Equity for LFCR at $1.3 million in Q2 2025, $2.2 million in Q1 2025, and $15.4 million in Q4 2024.